Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRNS 
Barinthus Biotherapeutics plc (BRNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: BRNS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.33% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.58M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 3 | Beta -0.69 | 52 Weeks Range 0.64 - 2.91 | Updated Date 11/7/2025 |
52 Weeks Range 0.64 - 2.91 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.34 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -360.87% |
Management Effectiveness
Return on Assets (TTM) -21.35% | Return on Equity (TTM) -53.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16296287 | Price to Sales(TTM) 3.25 |
Enterprise Value -16296287 | Price to Sales(TTM) 3.25 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -6.67 | Shares Outstanding 40827263 | Shares Floating 35690749 |
Shares Outstanding 40827263 | Shares Floating 35690749 | ||
Percent Insiders 13.62 | Percent Institutions 44.37 |
Upturn AI SWOT
Barinthus Biotherapeutics plc
Company Overview
History and Background
Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is a biopharmaceutical company dedicated to developing novel T cell immunotherapeutics designed to treat and prevent infectious diseases. Founded in 2016 as a spinout from the University of Oxford, the company has focused on harnessing the power of the immune system to combat diseases like chronic hepatitis B, human papillomavirus (HPV), and other infections.
Core Business Areas
- Infectious Disease Therapeutics: Focused on developing immunotherapies to treat and prevent infectious diseases, particularly those caused by viruses. This involves utilizing platform technologies to stimulate T cell responses against viral targets.
Leadership and Structure
The leadership team includes a CEO and other key executives overseeing research, development, and operations. The organizational structure is typical of a biopharmaceutical company, with departments focusing on research and development, clinical trials, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- VTP-300: An immunotherapeutic being developed for the treatment of chronic hepatitis B virus (HBV) infection. VTP-300 utilizes a prime-boost approach to stimulate T cell responses against HBV antigens. Competitors include companies developing direct-acting antivirals and other immunotherapies for HBV, such as Assembly Biosciences (ASMB). Market share data specific to VTP-300's future potential is unavailable, as it is still in clinical development.
- VTP-200: An immunotherapeutic being developed for the treatment of persistent HPV infections. Competitors include companies working on other HPV treatments and vaccines. Market share data specific to VTP-200's future potential is unavailable, as it is still in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, stringent regulatory requirements, and a lengthy drug development process. The market for infectious disease therapeutics is large and growing, driven by the increasing prevalence of infectious diseases worldwide.
Positioning
Barinthus Biotherapeutics plc is positioned as a developer of novel T cell immunotherapies for infectious diseases. Its competitive advantages lie in its proprietary platform technologies and experienced management team.
Total Addressable Market (TAM)
The total addressable market for infectious disease therapeutics is substantial, estimated in the billions of dollars annually. Barinthus Biotherapeutics plc is positioning itself to capture a share of this market by developing innovative therapies for unmet medical needs, particularly in areas like chronic HBV and HPV infection.
Upturn SWOT Analysis
Strengths
- Proprietary platform technologies for T cell immunotherapy
- Experienced management team
- Focus on unmet medical needs in infectious diseases
- Partnerships with leading research institutions
Weaknesses
- Dependence on successful clinical trial outcomes
- High research and development costs
- Limited commercial infrastructure
- Early stage of product development
Opportunities
- Expanding the pipeline to address additional infectious diseases
- Partnering with larger pharmaceutical companies for commercialization
- Securing regulatory approvals for lead product candidates
- Advancements in T cell immunotherapy technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- ASMB
- GILD
- ABBV
- BMY
Competitive Landscape
Barinthus Biotherapeutics plc faces competition from established pharmaceutical companies with greater resources and more advanced product candidates. Its competitive advantage lies in its innovative technology platform and focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early clinical development milestones.
Future Projections: Future growth is dependent on clinical trial success and potential commercialization of product candidates. Analyst estimates are highly variable.
Recent Initiatives: Recent strategic initiatives include advancing lead product candidates through clinical trials and exploring partnerships.
Summary
Barinthus Biotherapeutics plc is an early-stage biopharmaceutical company with a focus on developing T cell immunotherapies for infectious diseases. The company's success hinges on the outcome of its clinical trials and its ability to secure regulatory approvals. The company needs to secure partnerships to advance it product pipeline. It faces significant competition from larger, more established companies in the biopharmaceutical industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is an approximation and may not reflect precise values. Future projections are speculative and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Barinthus Biotherapeutics plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-04-30 | CEO, Director & Principal Financial Officer Mr. William J. Enright MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.barinthusbio.com |
Full time employees 105 | Website https://www.barinthusbio.com | ||
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.